AzTrials
AzTrials

Advanced Solid TumorPhase 1/2NCT05148533

A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

A Phase 1/2 study testing TJ1133 Injection in people with Advanced Solid Tumor, run by TJ Biopharma Co., Ltd. at 22 sites in China.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study is a phase I/II study of single drug TJ011133 and Toripalimab combine treatment forAdvanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension. The purpose of part A is to comfirm the MTD or MED and the clinical dose. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Advanced Solid Tumor
What is being tested?
TJ1133 Injection
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
7 participants
Where
22 sitesChina
Study dates
30 Dec 2021to 3 Feb 2023
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female subjects aged ≥18 years old (inclusive);
  • ECOG score: 0-1 points;
  • Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors, and those who failed or were intolerant to standard therapy, or have no effective treatment options:
  • Enrollment of patients with advanced solid tumors in the dose escalation phase;
  • Subjects with melanoma, gastric cancer, head and neck squamous cell carcinoma will be enrolled in the dose expansion phase;
  • Collect FFPE tumor tissue slides: Collect 12 to 13 archival pre-treatment (mandatory) and 10 on-treatment (optional) paraffin sections from fresh tumor biopsies.
Show all 39Show fewer
  • Subjects with at least 1 measurable lesion as per RECIST V1.1;
  • Expected survival ≥ 3 months;
  • Main organ function is normal (within 7 days prior to the first dose), i.e., relevant laboratory test criteria are met, and some laboratory indicators meet the following criteria:
  • Hematology: i. Hemoglobin ≥ 11.0 g/dL or 6.8 mmol/L, received no blood transfusion within 7 days of evaluation, and without dependence on erythropoietin (EPO), ii. Absolute neutrophil count (ANC) ≥1.5×109/L, iii. Platelets ≥ 75×109/L; b) Renal function: i. Creatinine clearance ≥ 45 mL/min (calculated by Cockcroft-Gault formula), ii. Qualitative urine protein ≤ 1+; or qualitative urine protein ≥ 2+, 24-hour urine protein < 1 g; c) Liver function i. Serum total bilirubin ≤ 1.5 × ULN, ii. Both aspartate aminotransferase (AST, SGOT) and alanine aminotransferase (ALT, SGPT) ≤ 2.5 × ULN, iii. Serum albumin ≥ 2.8 g/dL (received no albumin infusion within 2 weeks prior to blood collection); d) Coagulation function: i. International normalized ratio (INR), or prothrombin time (PT) ≤ 1.5 x ULN, or PT parameters can be maintained ≤ 1.5 x ULN with an anticoagulant at a stable dose, ii. Activated partial thrombin time (aPTT) ≤ 1.5 × ULN, or aPTT parameters can be maintained ≤ 1.5 × ULN with the use of anticoagulants;
  • Male subjects with reproductive potential and female subjects with pregnancy potential (which refer to men or women who have not been surgically sterilized, and women who are not post-menopausal) must use highly effective contraceptive methods such as oral contraceptives, intrauterine devices, sexual abstinence or barrier contraception in conjunction with spermicides during the course of the study and until 6 months after the last dose;
  • Subjects who are willing to participate in this study and sign the ICF, have good compliance and cooperate with the follow-up.
  • Subjects must be excluded if they meet any of the following criteria:
  • Pregnant or breast-feeding women;
  • Have received prior treatment with CD47 or SIRPα inhibitors;
  • Have received prior treatment with CAR-T cell therapy;
  • Have received systemic anti-tumor therapy within 4 weeks prior to the start of the study treatment, except for the following;
  • Have received nitrosoureas or mitomycin C within 6 weeks prior to the first dose of the investigational product;
  • Have received oral fluorouracils and small-molecule targeted agents within 2 weeks prior to the first dose of the investigational product or within 5 half-lives of the drug, whichever is longer;
  • Have received traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose of the investigational product.
  • With present or previous history of two or more primary tumors, except for cured carcinoma in situ and basal cell carcinoma. Subjects with concurrent tumors that have remained stable for more than 5 years prior to study enrollment are eligible;
  • Subjects who have active auto-immune diseases requiring systemic treatment with immunomodulatory drugs within 12 months prior to treatment initiation, but relevant alternative therapies are allowed;
  • Subjects who have received systemic treatment with corticosteroids (at doses higher than 10 mg/day prednisone or the equivalent) or other immunosuppressants for more than 7 days within 2 weeks prior to the start of the study treatment (use of inhaled or topical steroids or an adrenal replacement therapy at a dose exceeding 10 mg prednisone equivalents is acceptable in the absence of active auto-immune diseases);
  • Subjects who have received other unmarketed investigational drugs or treatment within 4 weeks prior to the start of the study treatment;
  • Subjects who have undergone major surgeries or were severely traumatized within 4 weeks prior to the start of the study treatment, or those who are recovering from such surgeries or traumas and the study results will be affected in the opinion of the investigator, or those have been scheduled to undergo surgeries during their participation in the study;
  • Have received chest radiotherapy or extended field radiotherapy (defined as more than 50% pelvic bone mass or equivalent) within 4 weeks prior to the initiation of study treatment, or palliative radiotherapy within 2 weeks prior to the initiation of treatment;
  • With the presence of symptomatic central nervous system (CNS) metastases and neurological instability or a need to increase the dose of corticosteroids to control CNS symptoms within 2 weeks prior to the start of the study treatment;
  • Have positive HBsAg and HBV-DNA > 500 IU/mL or the lower limit of detection of the study site [only if the lower limit of detection at the site is higher than 500 IU/mL]); HCV antibody positive and HCV-RNA quantitative detection is above the upper limit of normal;
  • With known positive human immunodeficiency virus (HIV) serum reaction;
  • With uncontrolled hydrothorax, ascites, or pericardial effusion;
  • Subjects who have or had prior active interstitial lung disease;
  • Subjects with hypertension that cannot be well controlled with drug therapies. Clinical uncontrollable hypertension is defined as a systolic blood pressure > 150 mm Hg or a diastolic blood pressure > 90 mm Hg (adjustment of anti-hypertensive drugs before the start of this study is acceptable, but the average blood pressure of the most recent three consecutive recordings must ≤ 150/90 mm Hg prior to enrollment of the study);
  • Adverse reactions to prior anti-tumor therapy have not recovered to Grade ≤ 1 as per CTCAE Ver 5.0 (except for toxicities that are judged by the investigator to have no safety risk, such as alopecia, Grade 2 peripheral neurotoxicity, hypothyroidism which is stable after hormone replacement therapy, etc.);
  • Have received immunotherapy and experienced Grade ≥ 3 irAEs or Grade ≥ 2 immune-related myocarditis;
  • Subjects with clinically significant cardiovascular disorder: including Grade II to IV cardiac insufficiency defined by the classification criteria of New York Heart Association (NYHA), congestive cardiac failure, heart block above Grade II, infarct myocardial within the past 3 months, unstable arrhythmia or unstable angina, significant QT interval prolongation (>450 ms for male and >470 ms for female); or cerebral infarction within the past 3 months, or surgical history of percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG) within the past 6 months;
  • With deep vein thrombosis within 6 months prior to the start of study treatment (except for the subjects who have not used the anti-coagulation agent of warfarin for more than 2 weeks prior to the start of the study treatment);
  • Thrombolytic therapy (except for the maintenance of an IV catheter) within 10 days prior to treatment initiation;
  • Any active infection requiring intravenous anti-infective therapy;
  • Subjects with known or suspected conditions (e.g., alcoholism, drug dependence, or psychological disorder) which render it impossible for them to comply with the protocol, or who may be at rick if they participate in this study according to the opinion of the investigator; or with the conditions in which subject's participation in this study is not their best option as judged by the investigator, (e.g., causing harm to health) or that affect, limit, or confound protocol assessments.

Who cannot join

  • Pregnant or breast-feeding women;
  • Prior treatment with CD47 or SIRPα inhibitors;
  • Prior CAR-T cell therapy;
  • Subjects who have received systemic anti-tumor therapies within 4 weeks prior to the initiation of treatment or within five half-lives (whichever is shorter) of the study drug, except for the following;
  • Nitrosourea or mitomycin C within 6 weeks prior to the first dose of study drug;
  • Oral fluorouracils and small molecule targeted agents are within 2 weeks prior to the first dose of study drug or within 5 half-lives of the drug, whichever is longer;
Show all 25Show fewer
  • Traditional Chinese medicine with anti-tumor indications is within 2 weeks prior to the first dose of study drug.
  • Subjects who had or have two or more primary tumors cannot be enrolled, except for cured carcinoma in situ and basal cell carcinoma. Subjects with concomitant tumors that have been stable for more than 5 years before enrollment in the study can be enrolled;
  • Subjects who have active auto-immune diseases requiring systemic treatment with immunomodulatory drugs within 12 months prior to treatment initiation, but relevant alternative therapies are allowed;
  • Subjects who have received systemic treatment with corticosteroids (more than 10 mg/day prednisone equivalent) or other immunosuppressants for more than 7 days within 2 weeks prior to treatment initiation (inhaled or topical steroids or adrenal replacement therapy in excess of 10 mg prednisone equivalents is permitted in the absence of active auto-immune disease);
  • Subjects who have participated in clinical trials (including investigational vaccines), and received interventional and investigational treatment with invasive and investigational medical devices within 4 weeks prior to the initiation of treatment;
  • Subjects who have experienced major surgery or severe trauma within 4 weeks prior to treatment initiation, or who are recovering, but which will exert an impact on the study as judged by the investigator, or who have surgical arrangements during their participation in the study;
  • Chest radiotherapy or expanded field radiotherapy (defined as more than 50% pelvic bone mass or equivalent) within 4 weeks prior to the initiation of treatment, or palliative radiotherapy within 2 weeks prior to the initiation of treatment;
  • Presence of symptomatic metastases to the central nervous system (CNS) and neurological instability within 2 weeks prior to initiation of dosing or a need to increase the dose of steroids to control CNS symptoms;
  • HBsAg positive and HBV-DNA copies > 500 IU/ml or lower limit of detection at the site (only if the lower limit of detection at the site is above 500 IU/ml); HCV antibody positive and result of HCV-RNA quantitative assay above the ULN;
  • Known positive human immunodeficiency virus (HIV) serum reaction;
  • Subjects with uncontrollable hydrothorax, ascites, or pericardial effusion;
  • Subjects who have or had active interstitial lung disease;
  • Subjects with hypertension that cannot be well controlled with drug therapies. Hypertension which cannot be controlled clinically is defined as a systolic blood pressure > 150 mmHg or a diastolic blood pressure > 90 mmHg (adjustment of treatment medications for hypertension is allowed before the initiation of this study, but the average blood pressure calculated from the most recent three consecutive recordings must ≤ 150/90 mmHg prior to his/her entry into the study);
  • Adverse reactions of prior anti-tumor therapy have not recovered to ≤ CTCAE 5.0 Grade 1 (except for alopecia, Grade 2 peripheral neurotoxicity and other toxicities judged by the investigator to have no safety risk);
  • Subjects with clinically significant cardiovascular disorder: including Grade II to IV cardiac insufficiency defined by the classification criteria of New York Heart Association (NYHA), congestive cardiac failure, heart block above Grade II, infarct myocardial within the past 3 months, unstable arrhythmia or unstable angina, significant QT interval prolongation (>450 ms for male and >470 ms for female); or cerebral infarction within the past 3 months, or surgical history of percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG) within the past 6 months;
  • Deep vein thrombosis within 6 months prior to the initiation of treatment (except for the case where warfarin has not been used for anti-coagulation for more than 2 weeks prior to treatment initiation);
  • Thrombolytic therapy (except for the maintenance of an IV catheter) within 10 days prior to treatment initiation;
  • Any active infection requiring intravenous anti-infective treatment;
  • Subjects with known or suspected conditions (e.g., alcoholism, drug dependence, or psychological disorder) which render it impossible for them to comply with the protocol, or who may be at risk if they participate in this study according to the opinion of the investigator; or with the conditions in which subject's participation in this study is not their best option as judged by the investigator, (e.g., causing harm to health) or that affect, limit, or confound protocol assessments.

Trial locations and contacts

22 sites in 1 country.

22 sites in 1 country

China22 sites

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, 33004

  • Jilin Cancer Hospital

    Changchun, Jilin, 130028

  • The First Hospital of Jilin University

    Changchun, Jilin, 130061

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, 410011

  • HuNan Cancer Hospital

    Changsha, Hunan, 410031

  • West China Hospital Sichuan University

    Chengdu, Sichuan, 610044

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, 350014

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, 510060

  • Guangzhou Medical University Affiliated Tumor Hospital

    Guangzhou, Guangdong, 510095

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310020

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, 150081

  • Anhui Province Cancer Hospital

    Hefei, Anhui, 230000

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, 230601

  • Shandong Tumor Hospital

    Jinan, Shandong, 250117

  • The first affiliated hospital of Nanchang University

    Nanchang, Jiangxi, 330006

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, 530031

  • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200011/201999

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, 200072

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality

  • Union Hospital Tongji Medical College Huazhong University Of Science And Technology

    Wuhan, Hubei, 430022

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430079

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450003

Other trials in China

About this study

Official title: A Phase I/II Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TJ011133 in Combination With Toripalimab in Subjects With Advanced Solid Tumors

This study is a phase I/II study of single drug TJ011133 and Toripalimab combine treatment forAdvanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension. The purpose of part A is to comfirm the MTD or MED and the clinical dose. The purpose of part B is to observe the safty, effectiveness, PK, PD and biomarker properties for effective subjects.

Read the detailed description

This is an open-label, multi-center phase I/II clinical trial which will enroll 96 to 102 subjects with advanced solid tumors.

This study consists of two phases, the first of which is the dose escalation study of TJ011133 in combination with toripalimab, and the second stage is a dose expansion study.

In phase 1, approximately 3 to 6 subjects will be enrolled in each group to receive TJ011133 (30 mg/kg, 45 mg/kg, QW) in combination with toripalimab injection (240 mg, Q3W). A safety assessment committee, consisting of the sponsor and the investigator, will assess the safety of the first 3 subjects at day 21 after the first dose to determine the safety of the doses as well as to determine whether to enroll 3 additional patients to continue to evaluate the safety.

In the dose expansion phase, patients with melanoma, gastric cancer, and head and neck squamous cell carcinoma will be enrolled, with 30 patients for each malignancy, with a total of 90 patients. TJ011133 will be administered at a prespecified dose of 30 mg/kg or 45 mg/kg, QW or at a less frequency of Q2W or Q3W, and the dosing regimen will be determined based on the safety data obtained by PK/PD model analysis from other TJ011133 clinical studies. And TJ011133 will be given in combination with toripalimab injection at 240 mg, Q3W, until the occurrence of endpoint events such as intolerance or progressive disease.

Being tested
TJ1133 Injection

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TJ1133 InjectionDrug

    TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)

Study groups in NCT05148533
Study groupRoleWhat they receive
TJ1133 InjectionExperimentalNot described
Receives: Drug: TJ1133 Injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence and Severity of Adverse Events

    The NCI CTCAE V5.0 will be used to assess adverse events on this study

    Measured: throughout the dose escalation assessed to 1year

  2. The Objective Response Rate(ORR)

    The Objective response rate will be assessed by RECIST v1.1 criteria in this study.

    Measured: Through the dose expansion assessed to 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Dec 2021
  2. Study start30 Dec 2021
  3. Primary completion3 Feb 2023
  4. Study completion3 Feb 2023

Why it stopped: Company Development strategy adjustment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
7 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05148533
Sponsor's protocol ID
TJ011133STM104
Status last verified
Apr 2024
First submitted
25 Nov 2021
Last updated
15 Apr 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing TJ1133 Injection in people with Advanced Solid Tumor, run by TJ Biopharma Co., Ltd. at 22 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 39 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 15 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 22 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Company Development strategy adjustment). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence and Severity of Adverse Events (time frame: throughout the dose escalation assessed to 1year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05148533.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in